Volpara Solutions Signs Agreement with GE Healthcare to Distribute Products to Help Improve Breast Cancer Screening for Women with Dense Breasts

WELLINGTON, New Zealand, Jan. 20, 2015 /PRNewswire/ -- To help improve breast cancer screening for the 40 percent of American women with dense breasts, Volpara Solutions announced today it has signed an agreement enabling GE Healthcare to distribute Volpara Solutions' industry-leading suite of products including VolparaDensity, VolparaAnalytics and VolparaDoseRT.

Under the agreement, GE Healthcare customers will have the option to purchase from GE Healthcare Volpara Solutions' innovative suite of quantitative breast imaging tools that enable personalized measurements of volumetric density, patient-specific dose, breast compression and other factors designed to provide critical insight for breast imaging quality and workflow.

"Volpara's volumetric density and breast imaging software are powerful tools which provide reliable, quantitative imaging data to help optimize breast cancer detection and patient care.  The objective and consistent measurement of breast density is critical to our ability to offer personalized breast evaluation and provide the right imaging test for the right woman," said Dr. Kathy Schilling, medical director of Christine E. Lynn Women's and Wellness Institute of Boca Raton Regional Hospital in Boca Raton, Florida. 

To date, more than 4-million women have had their breast density analyzed, using VolparaDensity, which is in use at breast imaging centers worldwide to help radiologists objectively assess density from both digital mammography and tomosynthesis images and to help determine which women with dense breasts may benefit from additional screening, such as with the GE Invenia Automated Breast Ultrasound (ABUS).

VolparaAnalytics is a powerful, centralized dashboard that produces configurable reports for management of quality assurance, resource utilization, and breast imaging workflow. VolparaDose provides a standardized measurement of patient-specific dose with consistent dose results across mammography systems from different manufacturers.

"Consistency in judging breast density and monitoring mammographic dose is becoming increasingly important in recommending supplemental imaging and in ensuring high quality patient care," said Ralph Highnam, PhD, Volpara Solutions CEO and Chief Scientist.  "We are pleased to work with GE Healthcare to offer customers the industry leading volumetric solution to help deliver excellent breast health care."

Putting advanced medical insights into the hands of clinicians, GE Healthcare's breast care solution is designed to address the needs of each unique woman: 3D breast tomosynthesis, automated breast ultrasound (ABUS), contrast-enhanced spectral mammography (CESM), molecular breast imaging (MBI), breast magnetic resonance imaging (MRI), healthcare IT workflows, and now Volpara's breast density technology. GE Healthcare's solution is the only to offer ABUS for screening asymptomatic women with dense breasts and 3D imaging, which provide clinicians with innovative tools to meet the unique needs of nearly half the female population with dense breasts and of women with all tissue types. A customized combination of these offerings can help enable confident and rapid diagnoses for women, and their unique breast health needs.

"We know that screening using our automated breast ultrasound has a 37% relative increase in cancer detection overall than mammography alone in women with dense breasts¹. Volpara's innovative technology provides an additional tool to help clinicians confidently and quickly determine a woman's breast density," said Jessie Jacob, MD, MMM, chief medical officer of Breast Health at GE Healthcare. "Together with Volpara's technology, our comprehensive breast care solution can further enable clinicians to detect early stage breast cancers and help improve the patient experience."

About Volpara Solutions
Founded to enable radiologists to give women the most accurate information possible regarding their breast health, Volpara Solutions is the wholly owned sales and marketing arm of Matakina Technology Limited of New Zealand.  Cleared by the FDA, HealthCanada, the TGA, and CE-marked, VolparaDensity provides an objectively volumetric measure of breast density from both digital mammography and tomosynthesis images. VolparaDensity is part of a suite of quantitative breast imaging tools built on the Volpara Solutions algorithm that allows for personalized measurements of density, patient dose, breast compression and other factors designed to help maintain accuracy and consistent quality in breast screening.  For more information, visit www.volparasolutions.com.

¹Assessing Improvement in Detection of Breast Cancer with Three-dimensional Automated Breast US in Women with Dense Breast Tissue: The SomoInsight Study.

Rachel F. Brem, MD, László Tabár, MD, Stephen W. Duffy, MSc, Marc F. Inciardi, MD, Jessica A. Guingrich, MD, Beverly E. Hashimoto, MD, Marla R. Lander, MD, Robert L. Lapidus, MD, Mary Kay Peterson, MD, Jocelyn A. Rapelyea, MD, Susan Roux, MD, Kathy J. Schilling, MD, Biren A. Shah, MD, Jessica Torrente, MD, Ralph T. Wynn, MD, Dave P. Miller, MS

Media Contacts:
Chris K. Joseph                                                                                                                         Volpara Solutions                                                                                            
510/435-4031                                                                                                  
[email protected]                                                                    

SOURCE Volpara Solutions

Related Links

http://www.volparasolutions.com

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED